129 related articles for article (PubMed ID: 2083186)
1. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma.
Gurney H; Crowther D; Anderson H; Murphy D; Prendiville J; Ranson M; Mayor P; Swindell R; Buckley CH; Tindall VR
Ann Oncol; 1990 Nov; 1(6):427-33. PubMed ID: 2083186
[TBL] [Abstract][Full Text] [Related]
2. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer.
Trask C; Silverstone A; Ash CM; Earl H; Irwin C; Bakker A; Tobias JS; Souhami RL
J Clin Oncol; 1991 Jul; 9(7):1131-7. PubMed ID: 2045855
[TBL] [Abstract][Full Text] [Related]
4. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles.
Murphy D; Crowther D; Renninson J; Prendiville J; Ranson M; Lind M; Patel U; Dougal M; Buckley CH; Tindall VR
Ann Oncol; 1993 May; 4(5):377-83. PubMed ID: 8353072
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
Mangioni C; Bolis G; Pecorelli S; Bragman K; Epis A; Favalli G; Gambino A; Landoni F; Presti M; Torri W
J Natl Cancer Inst; 1989 Oct; 81(19):1464-71. PubMed ID: 2674459
[TBL] [Abstract][Full Text] [Related]
6. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.
Dittrich Ch; Sevelda P; Salzer H; Obermair A; Speiser P; Breitenecker G; Schemper M; Kaider A;
Eur J Cancer; 2003 May; 39(8):1129-40. PubMed ID: 12736113
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study.
Alberts D; Mason N; Surwit E; Weiner S; Hammond N; Deppe G
Cancer Treat Rev; 1985 Sep; 12 Suppl A():83-92. PubMed ID: 3910225
[TBL] [Abstract][Full Text] [Related]
8. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.
Adams M; Kerby IJ; Rocker I; Evans A; Johansen K; Franks CR
Acta Oncol; 1989; 28(1):57-60. PubMed ID: 2650722
[TBL] [Abstract][Full Text] [Related]
10. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
12. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
[TBL] [Abstract][Full Text] [Related]
14. A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals.
Wrigley E; Weaver A; Jayson G; Ranson M; Renninson J; Prendiville J; Dobson M; Collins CD; Swindell R; Buckley CH; Radford JA; Crowther D
Ann Oncol; 1996 Sep; 7(7):705-11. PubMed ID: 8905028
[TBL] [Abstract][Full Text] [Related]
15. A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain.
Hidalgo M; Mendiola C; López-Vega JM; Castellano D; Mendez M; Batiste-Alenton E; López-Brea M; Belon J; Batista JN; Cortés-Funes H
Cancer; 1998 Aug; 83(4):719-25. PubMed ID: 9708936
[TBL] [Abstract][Full Text] [Related]
16. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma.
Böhm S; Oriana S; Spatti G; Di Re F; Breasciani G; Pirovano C; Grosso I; Martini C; Caraceni A; Pilotti S; Zunino F
Oncology; 1999; 57(2):115-20. PubMed ID: 10461057
[TBL] [Abstract][Full Text] [Related]
17. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
[TBL] [Abstract][Full Text] [Related]
18. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
Weiss G; Green S; Alberts DS; Thigpen JT; Hines HE; Hanson K; Pierce HI; Baker LH; Goodwin JW
Eur J Cancer; 1991; 27(2):135-8. PubMed ID: 1827275
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
McGuire WP; Arseneau J; Blessing JA; DiSaia PJ; Hatch KD; Given FT; Teng NN; Creasman WT
J Clin Oncol; 1989 Oct; 7(10):1462-8. PubMed ID: 2674333
[TBL] [Abstract][Full Text] [Related]
20. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
